- Sonoma Pharmaceuticals (NASDAQ:SNOA) +35.3% post-market after announcing a partnership with Crown Laboratories for a license and supply agreement for exclusive rights to sell and market products for the over-the-counter dermatological market in the U.S.
- Under the deal terms, Crown will sell Sonoma's Microcyn technology dermal sprays and gels targeting itch and pain under the Sarna brand.
- Sonoma will continue to sell its prescription strength products, while Crown will distribute an OTC version available without prescription.
- https://seekingalpha.com/news/3643562-sonoma-pharmaplus-35-on-crown-laboratories-partnership
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.